In our previous work based on the lead SR 142948A, we developed the first 18F-fluoroglycosylated NTSR1 antagonist (Ki (NTSR1) = 0.98 nM) with excellent biodistribution, rapid clearance from blood, and specific NTSR1-mediated tumor uptake in HT-29 tumor-bearing mice, as demonstrated by PET imaging [24]. This evidence concerns the gene NTSR1 and neoplasm.